OssDsign held its annual general meeting on 9 June 2026
Resolutions included adoption of financial statements, board elections, and approval of a long-term incentive program.
See the latest news and media coverage for OssDsign. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of next-generation orthobiologics
ossdsign.comLast updated
In short: OssDsign focused on U.S. commercial expansion, leadership transitions, and reported 100% spinal fusion success in clinical study results.
Resolutions included adoption of financial statements, board elections, and approval of a long-term incentive program.
The preclinical study shows significantly more bone formation and natural resorption of the graft over 26 weeks.
Net sales decrease 17.1% to TSEK 36,879. Gross margin is 91.6%. EBIT is TSEK -13,466. Investor webcast held on May 5.
The report is available as PDF on the company's website and attached to the press release. CEO Mark Waugh emphasizes building clinical evidence.
The medical technology company Ossdsign, with operations in implants for cranial reconstruction, reports an operating result of -13.5 million kronor for...
"A commitment to building clinical evidence remains a cornerstone of the commercialization strategy and continues to differentiate OssDsign in the market" said Mark Waugh, CEO...
OssDsign AB (publ.) announces today that the preliminary revenue for the period January-March 2026 amounts to 4.035 million USD or 36.880 million SEK.
Close Panel: The elite is misbehaving - I'm buying commodities.Friday panel with Peter Benson and Love Strandberg. There will be talk about the week that has been, Elon Musk...
Track OssDsign and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to OssDsign and other trending companies.